TY - STD TI - U.S. Food and Drug Administration. CDRH’S APPROACH TO TUMOR PROFILING NEXT GENERATION SEQUENCING TESTS. Silver Spring, MD: U.S. Food and Drug Administration; 2017. https://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/UCM584603.pdf. UR - https://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/UCM584603.pdf ID - ref1 ER - TY - STD TI - FDA. EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets). 2017;:1–57. doi:https://doi.org/10.1164/rccm.201205-0815OC. ID - ref2 ER - TY - JOUR AU - Tsimberidou, A. -. M. AU - Iskander, N. G. AU - Hong, D. S. AU - Wheler, J. J. AU - Falchook, G. S. AU - Fu, S. PY - 2012 DA - 2012// TI - Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-1627 DO - 10.1158/1078-0432.CCR-12-1627 ID - Tsimberidou2012 ER - TY - JOUR AU - Stockley, T. L. AU - Oza, A. M. AU - Berman, H. K. AU - Leighl, N. B. AU - Knox, J. J. AU - Shepherd, F. A. PY - 2016 DA - 2016// TI - Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial JO - Genome Med VL - 8 UR - https://doi.org/10.1186/s13073-016-0364-2 DO - 10.1186/s13073-016-0364-2 ID - Stockley2016 ER - TY - JOUR AU - Arango, N. P. AU - Brusco, L. AU - Shaw, K. R. M. AU - Chen, K. AU - Eterovic, A. K. AU - Holla, V. PY - 2017 DA - 2017// TI - A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.16018 DO - 10.18632/oncotarget.16018 ID - Arango2017 ER - TY - JOUR AU - Hilal, T. AU - Nakazawa, M. AU - Hodskins, J. AU - Villano, J. L. AU - Mathew, A. AU - Goel, G. PY - 2017 DA - 2017// TI - Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy JO - BMC Cancer VL - 17 UR - https://doi.org/10.1186/s12885-017-3587-8 DO - 10.1186/s12885-017-3587-8 ID - Hilal2017 ER - TY - JOUR AU - Jordan, E. J. AU - Kim, H. R. AU - Arcila, M. E. AU - Barron, D. AU - Chakravarty, D. AU - Gao, J. PY - 2017 DA - 2017// TI - Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-1337 DO - 10.1158/2159-8290.CD-16-1337 ID - Jordan2017 ER - TY - JOUR AU - Sireci, A. N. AU - Aggarwal, V. S. AU - Turk, A. T. AU - Gindin, T. AU - Mansukhani, M. M. AU - Hsiao, S. J. PY - 2017 DA - 2017// TI - Clinical genomic profiling of a diverse Array of oncology specimens at a large academic Cancer center JO - J Mol Diagnostics VL - 19 UR - https://doi.org/10.1016/j.jmoldx.2016.10.008 DO - 10.1016/j.jmoldx.2016.10.008 ID - Sireci2017 ER - TY - JOUR AU - Tsimberidou, A. -. M. AU - Hong, D. S. AU - Ye, Y. AU - Cartwright, C. AU - Wheler, J. J. AU - Falchook, G. S. PY - 2017 DA - 2017// TI - Initiative for molecular profiling and advanced Cancer therapy (IMPACT): an MD Anderson precision medicine study JO - JCO Precis Oncol VL - 2017 UR - https://doi.org/10.1200/PO.17.00002 DO - 10.1200/PO.17.00002 ID - Tsimberidou2017 ER - TY - JOUR AU - Schram, A. M. AU - Reales, D. AU - Galle, J. AU - Cambria, R. AU - Durany, R. AU - Feldman, D. PY - 2017 DA - 2017// TI - Oncologist use and perception of large panel next-generation tumor sequencing JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx294 DO - 10.1093/annonc/mdx294 ID - Schram2017 ER - TY - JOUR AU - Green, R. C. AU - Berg, J. S. AU - Grody, W. W. AU - Kalia, S. S. AU - Korf, B. R. AU - Martin, C. L. PY - 2013 DA - 2013// TI - ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing JO - Genet Med VL - 15 UR - https://doi.org/10.1038/gim.2013.73 DO - 10.1038/gim.2013.73 ID - Green2013 ER - TY - JOUR AU - Zon, R. T. AU - Edge, S. B. AU - Page, R. D. AU - Frame, J. N. AU - Lyman, G. H. AU - Omel, J. L. PY - 2017 DA - 2017// TI - American Society of Clinical Oncology criteria for high-quality clinical pathways in oncology JO - J Oncol Pract VL - 13 UR - https://doi.org/10.1200/JOP.2016.019836 DO - 10.1200/JOP.2016.019836 ID - Zon2017 ER - TY - STD TI - Daly B, Zon RT, Page RD, Edge SB, Lyman GH, Green SR, et al. Oncology Clinical Pathways: Charting the Landscape of Pathway Providers. J Oncol Pract. 2018;14:e194–200. https://doi.org/10.1200/JOP.17.00033. ID - ref13 ER -